Corporate Information

7327 Oak Ridge Hwy

Knoxville, TN 37931

Phone: (866) 594-5999
Fax: (866) 998-0005

www.pvct.com

Recent News Releases

Provectus Pharmaceuticals Forms Independent Board to Meet Corporate Governance Requirements

Monday, May 14, 2012

Provectus announces the Company has formed an independent board to meet corporate governance requirements like that of NASDAQ, which requires a majority of independent Board Members.

Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presented At 2nd European PostASCO Melanoma Meeting 2012 on June 22, 2012

Wednesday, May 9, 2012

Provectus announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

Monday, May 7, 2012

Provectus today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing.

Follow Crystal Research

Provectus Pharmaceuticals, Inc.

Corporate Snapshot

Provectus Pharmaceuticals, Inc. ("Provectus" or "the Company") is developing advanced prescription drugs in the fields of oncology and dermatology, which are designed to target and destroy the deadliest of cancers and to treat severe skin diseases such as psoriasis, respectively. The Company is also developing biotechnologies to augment vaccine production and detect viruses (including an innovative "virus hunter" method). To supplement its development efforts, Provectus produces and markets over-the-counter (OTC) skin care products, and licenses patented technologies for therapeutic and cosmetic medical devices. Its oncology portfolio contains Provecta™, an injectable oncology drug in development to treat melanomas, and focal tumors of the breast, liver, and prostate. Its dermatology portfolio contains Xantryl™, a topical drug in development to treat psoriasis and other dermatology disorders including acne, actinic keratosis (AK), and eczema. The Company's therapeutic device technologies are focused in three main areas: (1) the treatment of ocular melanomas; (2) the improvement of multiphoton microscopy and diagnostic devices; and (3) devices that cut tissue for precise surgical applications, such as laser vision correction. Provectus currently markets an antibacterial hand and surface spray called Pure-ific™, which immediately eradicates up to 99.9% of germs on the skin and prevents regrowth for six hours. The Company has also conducted a pilot-scale run on the manufacturing of a hand cream, which contains both antiperspirant and antibacterial properties, called GloveAid™, to treat the irritation associated with wearing disposable gloves. A second-stage product, called Pure-Stick™, is a non-toxic, topical agent to treat acne.